Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

被引：0
|
作者：
Mikio Sugimoto
Takuma Kato
Yoichiro Tohi
Yosuke Shimizu
Ryuji Matsumoto
Takahiro Inoue
Yutaka Takezawa
Kimihiko Masui
Hiroshi Sasaki
Hiromi Hirama
Shiro Saito
Shin Egawa
Toshiyuki Kamoto
Satoshi Teramukai
Shinsuke Kojima
Takashi Kikuchi
Yoshiyuki Kakehi
机构：
[1] Kagawa University,Department of Urology, Faculty of Medicine
[2] Kobe City Nishi-Kobe Medical Center,Department of Urology
[3] Hokkaido University Graduate School of Medicine,Department of Urology
[4] Kyoto University,Department of Urology, Graduate School of Medicine
[5] Isesaki Municipal Hospital,Department of Urology
[6] Otsu City Hospital,Department of Urology
[7] Jikei University School of Medicine,Department of Urology
[8] National Hospital Organization Tokyo Medical Center,Department of Urology
[9] University of Miyazaki,Department of Urology, Faculty of Medicine
[10] Kyoto Prefectural University of Medicine,Department of Biostatistics
[11] Foundation for Biomedical Research and Innovation at Kobe Translational Research Center for Medical Innovation,undefined
来源：
BMC Urology | / 22卷
关键词：
Combined androgen blockade; Enzalutamide; Non-metastatic castration-resistant prostate cancer; Progression-free survival; Radical treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Physician preferences for non-metastatic castration-resistant prostate cancer treatment
    Sandy Srinivas
    Ateesha F. Mohamed
    Sreevalsa Appukkuttan
    Marc Botteman
    Xinyi Ng
    Namita Joshi
    Erica Horodniceanu
    A. Reginald Waldeck
    Stacey J Simmons
    BMC Urology, 20
  • [22] Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer
    Alekseev, B. Ya
    Nushko, K. M.
    Kozlova, P. S.
    Kaprin, A. D.
    Mailyan, O., I
    ONKOUROLOGIYA, 2020, 16 (03): : 190 - 197
  • [23] PROSPER: A phase 3 study of enzalutamide (ENZA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
    Tombal, B.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N. D.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    SWISS MEDICAL WEEKLY, 2018, 148 : 15S - 15S
  • [24] Clinical characteristics and outcomes for patients with non-metastatic castration-resistant prostate cancer
    Arnold, Peter
    Penaloza-Ramos, Maria Cristina
    Adedokun, Lola
    Rees, Sarah
    Lockhat, Mohamed
    Spary, Lisa
    Watkins, Alan
    Gnanapragasam, Vincent
    Crabb, Simon J.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [25] A new androgen receptor antagonist Darolutamide for patients with non-metastatic castration-resistant prostate cancer
    Kesch, C.
    Hadaschik, B. A.
    UROLOGE, 2019, 58 (10): : 1217 - 1218
  • [26] Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management
    Alfredo Tartarone
    Rosa Lerose
    Marina Tartarone
    Medical Oncology, 39
  • [27] Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2022, 17 : 381 - 381
  • [28] Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment
    Anantharaman, Archana
    Small, Eric J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (07) : 625 - 633
  • [29] New Treatment Option - Apalutamide for non-metastatic, castration-resistant Prostate Cancer
    Hadaschik, B.
    Panic, A.
    UROLOGE, 2018, 57 (06): : 729 - 730
  • [30] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSES OF ENZALUTAMIDE FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN MEXICO
    Ruiz, B.
    Polanco, A.
    Saturnino, L. T. M.
    Flores Aldana, B. A.
    Gutierrez, M.
    VALUE IN HEALTH, 2022, 25 (12) : S139 - S140
12345